2022 Memorium
Sadly, too many of our rheumatology colleagues passed on in 2022. Here is an (incomplete) list of notable brethren, mentors, do-gooders and great rheumatologists:
News
2022 Rheumatology Year in Review (1-6-2023)
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
2022 Rheumatology Year in Review
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Lubricin as a Treatment Target in Gout?
EurekAlert!
Many Americans think of gout as a disease from a bygone era, akin to rickets or scurvy. The condition commonly afflicted the rich and royal, including American historical figures such as Benjamin Franklin and Thomas Jefferson.
Drug Price Increases Continue in 2023
Reuters reports that in 2023, drug makers intend to increase the price of over 350 drugs.
In Giant Cell Arteritis, Hospital Admission Is Bad News
MedPage Today
One-third of patients admitted with giant cell arteritis (GCA) were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study.
ACP Recommends Bisphosphonates as Initial Therapy for Osteoporosis
EurekAlert!
The American College of Physicians (ACP) has issued an update of its guideline with clinical recommendations for treatments of primary osteoporosis and low bone mass in adults.
2022 Match - Strong Appeal of Adult Rheumatology, Less So in Pediatric Rheumatology
ACR
The American College of Rheumatology is pleased to announce another successful recruitment season and welcomes this impressive pool of applicants to the field of rheumatology.
Extreme Global Costs of Physical Inactivity
A global, population-based study shows that physical inactivity is not only an important modifiable risk factor for non-communicable diseases (NCDs) and mental health conditions, it also imparts a considerable health and economic burden that is avoidable.
Best of 2022: Allopurinol Safety in CKD Patients
A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.
Best of 2022: Emerging Therapeutics for Lupus
Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of four exciting abstracts presented at the meeting with emerging therapeutics designed to slay the beast.
